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Background: The study aimed to assess the level of plasma Endothelin-1 (ET-1) in patients before and after
transcatheter closure of atrial septal defect (ASD) and to evaluate the usefulness of measuring ET-1 levels for the
diagnosis and selection of candidates for ASD closure.
Methods: 80 patients (55 F, 25 M), mean age 42,2 ± 11,5 years were enrolled for an attempt at ASD closure. A
group of 19 healthy volunteers, (12 F, 7 M) mean age 39.2 ± 9.15 served as controls. All ASD patients underwent:
clinical and echocardiographic study and cardiopulmonary exercise test. ET-1 levels were measured before and
after closure. Whole blood was collected from femoral artery and vein and from pulmonary artery during cardiac
catheterization.
Results: ET-1 levels at peripheral artery and vein in ASD patients were significantly higher than in the volunteers
(p < 0.0001). The ASD subjects with highest ET-1 level presented the larger area of right ventricle and right atrium
and higher pulmonary artery systolic pressure(p < 0.05). The ASD subjects with lower ET-1 level demonstrated longer
time of exercise and higher peak oxygen consumption (p < 0.05). There was a decrease of ET-1 at peripheral artery
(5.128 ± 8.8 vs. 2.22 ± 6.2; p < 0.001) and at peripheral vein (4.401 ± 3.33 vs. 2.05 ± 1.35; p < 0.001) within 48 hours
after ASD closure, as compared to the baseline data. After 6 and 12 months farther drop in ET-1 level was observed.
Conclusions: 1. The level of ET-1 in ASD patients is elevated in compare to healthy subject.
2. The significant reduction of ET-1 level is observed after percutaneous closure of ASD.
3. Elevated level of ET-1 in patients with ASD is associated with right heart enlargement.
4. Measurements of ET-1 may be a supplemental diagnostic tool and may be helpful in establishing indications for
defect closure.
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Closure of an atrial septal defect (ASD) in patients with
hemodynamically significant shunt has become standard
of care in recent years. Correction of ASD prevents
the development of pulmonary hypertension, cardiac
arrhythmia and heart failure [1-4]. The indications for
ASD closure in adults however are ambiguous. The most
controversial issue is selection of candidates for ASD
closure who have normal pulmonary artery pressure,
absent or negligible clinical symptoms and are over 40 years
of age [5-9].* Correspondence: moni_s@interia.pl
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unless otherwise stated.In light of divergent opinions regarding ASD correction
in all patients irrespective of age and clinical symptoms
it appears necessary to look for novel diagnostic and
prognostic indicators that may become useful for proper
selection of candidates for ASD closure.
Endothelins (ET) comprise a family of three isopeptides:
endothelin-1, -2, and -3. ET-1 is released mainly from
endothelial cells and cardiomyocytes and is probably the
most important isoform in the regulation of cardiovas-
cular function [10,11].
ET-1 is thought to play an important role in the patho-
genesis of pulmonary hypertension, both primary and
secondary [12-14]. Jia B et al. [14] demonstrated elevated
plasma ET-1 concentration in children with ventricularLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Komar et al. Cardiovascular Ultrasound 2014, 12:31 Page 2 of 8
http://www.cardiovascularultrasound.com/content/12/1/31and atrial septal defects that correlated with pulmonary
artery pressure. After surgical repair of the defects, plasma
ET-1 concentration decreased significantly. In patients
with ASD and associated elevated pulmonary artery
pressure it seems important to measure ET-1 levels
before and after ASD closure, to investigate the potential
benefits of ET-1 receptor blockers and to establish the
prognostic value of ET-1.
Aim of the study
 to assess the level of plasma Endothelin-1 in patients
with atrial septal defect
 to evaluate the usefulness of measuring ET-1 levels
for the diagnosis and selection of candidates for
ASD closure
Material and methods
The study included 80 consecutive adult patients, 55
women (68.75%) and 25 men (31.25%), who underwent
percutaneous closure of ASD with an Amplatzer device
in the Department of Hemodynamics and Angiography,
Institute of Cardiology, Jagiellonian University Medical
College. The mean age of the patients was 42.2 ± 11.5
(range 18-65).
A group of 19 healthy volunteers, 12 women (61.2%)
and 7 men (36.8%) with a mean age of 39.2 ± 9.15 (range
18-51), matched for age and gender served as controls.
The secundum atrial septal defect (ASD II) was diag-
nosed on the basis of clinical examination and transthoracic
echocardiography (TTE) whereas transesophageal echocar-
diography (TEE) was performed to select candidates for
percutaneous ASD closure. Diagnosis was confirmed dur-
ing cardiac catheterization immediately before the Amplat-
zer deployment. The following parameters were measured:
 pulmonary artery pressure at systole (PAPs),
 total pulmonary vascular resistance (TPVR),
 pulmonary blood flow (Qp),
 systemic blood flow (Qs),
 pulmonary/systemic blood flow ratio (Qp/Qs).
Patients were considered for transcatheter closure if they
had a single secundum atrial septal defect with a diameter
measuring less than 30 mm on echocardiography with a rim
of tissue of at least 5 mm surrounding the defect located in
the central part of the septum and with a hemodynamically
significant left-to-right shunt (Qp/Qs > 1.5:1). Two patients
had two defects that were so close to each other that it was
possible to close them with one device.
All patients underwent preoperative diagnostic procedures:
 Clinical examination including assessment of
NYHA class Transthoracic echocardiography to measure right
ventricular area at diastole (RVarea [cm
2]) and right
atrial area at diastole (RAarea)
 Spirometry at rest to measure forced vital capacity
expressed as a percentage of the normal value (FVC
%), forced expiratory volume in one second expressed
as a percentage of the normal value (FEV1%)
 Exercise spirometry test to measure duration of
exercise in seconds (T), peak oxygen consumption
VO2peak(ml/kg/min), time to anaerobic threshold
(TAT), oxygen consumption at the anaerobic
threshold (VO2AT%), ventilatory equivalent for
carbon dioxide (VE/VCO2)
Measurement of endothelin levels
Endothelin-1 levels were measured immediately before
and at 2 days, 6 and 12 months after transcatheter closure.
Whole blood was collected from femoral artery and
femoral vein in each ASD II patient before the procedure
and in volunteers. Additionally, blood samples were col-
lected from pulmonary artery during diagnostic cardiac
catheterization. After transcatheter closure blood was
sampled from femoral artery and femoral vein.
Whole blood was collected in precooled tubes contain-
ing EDTA and aprotinine (1 vol of anticoagulant for 9 vol
of blood) and immediately placed on ice. The blood was
then centrifuged to the freezing temperature at 3000 rpm
for 10 min. The platelet-poor plasma was frozen in
tubes and sent to the laboratory. Measurements of ET-
1 were done at the Biochemical Laboratory of the John
Paul II Hospital in Krakow. ET-1 was measured with a
commercial immunoenzymatic ELISA method and results
expressed as fmol/ml. The study protocol was approved
by the Bioethics Committee of the Jagiellonian University
Medical College (KBET/262/B/2002).
Analysis was performed in the whole group and in two
subgroups with the high and low plasma ET-1 levels in
the pulmonary artery:
 Subgroup G – ET-1 levels from 0.91 to 2.81 fmol/ml
 Subgroup H – ET-1 levels from 7.13 to 24.68 fmol/ml
Patient characteristics in subgroup G and H are sum-
marized in Table 1.
To allocate patients to the subgroups ET-1 values were
sorted in ascending order to define the median and
quartiles. Those who had ET-1 levels in the first quartile
were allocated to subgroup G and those with ET-1 levels
in the fourth quartile to subgroup H (Figure 1).
Statistical analysis
The discrimination value of selected parameters was
determined by comparing two subgroups with the low
and high ET-1 levels and ROC analysis was performed
Table 1 Patient characteristics in subgroup G and H with
the low and high ET01 levels, respectively
Subgroup G n = 30 Subgroup H n = 38 p
ET-1 (fmol/ml) 1.81 ± 1,3 (0.91-2.81) 9.4 ± 9.2 (7.72-24.68) <0,0001
Women 20 (66.7%) 25 (65.9%) NS
Men 10 (33.3%) 13 (34.1%) NS
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specificity. The Peto method was then used to perform
meta-analysis ad calculate odds ratios (OR) for individual
risk factors. The Peto method also allowed for assessment
of multidimensional risk of elevated ET-1 levels. OR were
calculated with corresponding 95% confidence intervals
(95% CI).
Multivariate analyses such as multiple forward stepwise
regression, logistic regression and canonical correlation
were used to evaluate the parameters affecting ET-1 levels.
Stepwise and logistic regression allowed for estimation
of the effect of independent variables on the dependent
variable i.e. endothelin levels. Statistical significance was
set at α ≤0.05. Statistical analyses were performed using
Statistica 6.0. Meta-analysis and ROC analysis were per-
formed using StatsDirect 2.1.
Results
An Amplatzer device was implanted without major com-
plications in all eligible patients. Minor complications
during transcatheter closure included transient supra-
ventricular tachycardia in 5 patients (6.25%) and transi-
ent bradycardia to 30 bpm in one patient (1.25%). 5
patients (6.25%) had a hematoma at the femoral puncture
site. The mean duration of the procedure including diag-
nostic right-heart catheterization was 41.0 ± 7.2 (20-65)
min and the mean fluoroscopy time 12.2 ± 4.42 (5-27) min.
The size of Amplatzer devices ranged from 13 to 40 mm
(mean 24.2 ± 6.9 mm). Immediately after deployment of theFigure 1 Plasma ET-1 levels in the pulmonary artery in patients with
vertical bars denote the first and fourth quartile).device TEE revealed nonsignificant residual shunt in 8
patients (10%) persisting 2 days after the procedure TTE
and resolving at 6 months of follow-up in each case.
ET-1 levels before and after transcatheter closure
Table 2 summarizes ET-1 levels in patients before and after
transcatheter closure of ASD II and in healthy volunteers.
Patients before transcatheter closure of ASD II had
significantly higher ET-1 levels both in peripheral artery
and in peripheral vein as compared with healthy volun-
teers (p < 0.0001). The minimum detectable level of ET-1
in the peripheral artery and vein in ASD patients was
higher than the maximum level in healthy volunteers. The
highest level of ET-1 was detected in the pulmonary artery
in ASD patients (mean 5.541 ± 6.87).
After transcatheter closure ET-1 levels significantly
decreased both in peripheral artery and vein in all
patients. Figures 2 and 3 depict ET-1 levels in the per-
ipheral artery and vein before and after transcatheter
closure of ASD II.
As early as 48 hours after ASD II closure the level of
ET-1 was significantly reduced both in the peripheral artery
(2.10 ± 6.7; p < 0.001) and vein (2.05 ± 1.15; p < 0.001). At
6 months the levels of ET-1 were further reduced to a mean
of 0.49 ± 0.17 in the peripheral artery and to 0.40 ± 0.19 in
the peripheral vein. At 12 months there was no further sig-
nificant decrease as compared with the levels at 6 months.
At 12 months after transcatheter closure there was still a
significant difference in ET-1 levels both in the peripheral
artery (0.049 ± 0.025 vs. 0.49 ± 0.17, p < 0.001) and in the
peripheral vein (0.054 ± 0.027 vs. 0.40 ± 0.19, p < 0.001)
between patients with closed ASD and healthy volunteers.
Selected parameters, including hemodynamics and
physical capacity, were compared in two subgroups with
the high (subgroup H - ET-1 levels from 7,13 to 24,68
fmol/ml) and low (subgroup G – ET-1 levels from 0,91
to 2.81 fmol/ml) ET-1 levels in the pulmonary artery.ASD II before transcatheter procedure – sorted by quartiles (gray
Table 2 ET-1 levels in patients before transcatheter closure of ASD II and in healthy volunteers
Group Vessel Mean Minimum Maximum SD p ASD II vs. healthy
ASD II patients before closure n = 80 Peripheral artery 6,122 0,772 13,981 3,651 < 0,0001
Peripheral vein 4,431 1,230 13,546 3,312 < 0,0001
Pulmonary artery 5,541 0,91 24,68 6,874 -
Healthy volunteers n = 19 Peripheral artery 0,049 0,010 0,098 0,025 < 0,0001
Peripheral vein 0,054 0,001 0,099 0,027 < 0,0001
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those in subgroup G.
ASD II patients with the high ET-1 level had signifi-
cantly increased right atrial and right ventricular area and
higher pulmonary artery pressures.
ASD II patients with the low ET-1 level had higher peak
oxygen consumption and at the anaerobic threshold
(p < 0.05) and time to anaerobic threshold was signifi-
cantly prolonged (p < 0.01). The ventilatory equivalent
for carbon dioxide was significantly lower in subgroup
G. Table 3 summarizes the results of the comparative
analysis.
The canonical correlation analysis showed that the
following parameters had an influence on ET-1 levels in
pulmonary artery, peripheral artery and vein: PAPs,
Qp/Qs, age, RVarea (cm
2), RAarea (cm
2), size of ASD II,
VO2peak (ml/kg/min), FVC (%), VO2AT%; p < 0.05.
The multiple forward stepwise regression analysis re-
vealed that of all parameters [(PAPs, Qp/Qs, age, RVarea
(cm2), RAarea (cm
2), size of ASD II, VO2peak (ml/kg/min),
FVC (%), VO2AT%, TAT)] PAPs (F(7.25) = 9.1785; p < 0.0001,
standard error 2.170) had the strongest influence on ET-1
levels.
Higher ET-1 levels before closure don’t predict higher
pulmonary artery pressure/resistances after closure.Figure 2 ET-1 levels in the peripheral artery before and after transcatROC curves for selected parameters influencing ET-1
levels and meta-analysis using the Peto method are
depicted in Figures 4, 5 and 6.
The cut-off values defined in the meta-analysis and
increasing the risk of elevated ET-1 levels in ASD II
patients are as follows:
 Right atrial area (RAarea) > 17.81 mm (p < 0.0002)
 Right ventricular area (RVarea) > 23.508 mm
(p < 0.0014)
 Age > 40 years (p < 0.0002)
 Pulmonary artery pressure at systole
(PAPs) > 31.04 mmHg (p < 0.0001)
 Peak oxygen consumption (VO2peak) < 23.022 ml/kg/
min (p < 0.0002)
 Forced vital capacity (FVC) < 90.07% (p < 0.0115)
 Time to anaerobic threshold (TAT) < 423.16 second
(p < 0.0006)
 Oxygen consumption at the anaerobic threshold
(VO2AT%) < 39.016%VO2 (p < 0.0128)
Discussion
Percutaneous closure of interatrial septal defects has be-
come a standard therapeutic approach in the last few years.
Correction of the defect may prevents the development ofheter closure of ASD II.
Figure 3 ET-1 levels in the peripheral vein before and after transcatheter closure of ASD II.
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the heart. Amplatzer Septal Occluders have been com-
monly used for defect closure since the 90s [1,3,5,6].
Elevated circulating ET-1 is observed in patients with
left-to-right shunt and pulmonary hypertension indicat-
ing that pulmonary vessels are responsible for increased
ET-1 synthesis [14].
Endothelin is probably one of the key contributors to
the pathogenesis of pulmonary hypertension [12-14].Table 3 Selected parameters in patients with the high
(subgroup H) and low (subgroup G) ET-1 levels in the
pulmonary artery
Subgroup G – ET1
from 0,91 to
2,81 fmol/ml
Subgroup H – ET1
from 7,13 to
24,68 fmol/ml
P
Age 35,1 ± 11,43 56,36 ± 5,7 <0,001
Defect size 23,1 ± 7,28 18,9 ± 4,28 NS
RVarea (cm
2) 23,1 ± 1,01 25 ± 1,51 < 0,01
RAarea (cm
2) 16,2 ± 1,2 19,5 ± 0,9 <0,001
PAPs (mmHg) 20,1 ± 5,2 40,01 ± 19,5 <0,01
Qp (l/min) 8,4 ± 2,41 8,7 ± 2,5 NS
COP (dyn/s/cm−5) 140,1 ± 24,8 189 ± 130,1 NS
Qp/Qs 2,20 ± 1,31 2,34 ± 1,4 NS
T (s) 734 ± 71,45 700,7 ± 90,1 NS
VO2peak
(ml/kg/min)
24,13 ± 3,32 21,1 ± 3,92 <0,05
FVC% 107,6 ± 14,0 89,5 ± 4,7 <0,05
FEV1% 93,5 ± 10,2 87,3 ± 17 NS
TAT (s) 455,6 ± 44,9 390 ± 23,1 <0,01
VO2AT% 41,4 ± 2,8 35,41 ± 4,5 <0,05
VE/VCO2 30,4 ± 3,1 39 ± 4,4 <0,05
NYHA 1,9 ± 1,08 2,39 ± 1,03 NSIn the present study ASD II patients before transcathe-
ter closure had significantly higher ET-1 levels both in
peripheral artery and vein as compared with healthy vol-
unteers. The minimum detectable ET-1 in the peripheral
artery and vein in ASD II patients was higher than the
maximum ET-1 level in healthy volunteers. The highest
ET-1 level was detected in the pulmonary artery in ASD II
patients. The multiple forward stepwise regression analysis
revealed that pulmonary artery pressure had the strongest
influence on ET-1 levels. These findings are concordant
with the results obtained by other investigators [15-19].
The high circulating ET-1 as compared with healthy
volunteers is accounted for by increased pulmonary
blood flow, increased pulmonary pressure and increased
synthesis of ET-1 [13-19].
ET-1 levels decreased significantly both in the peripheral
artery and the peripheral vein in all patients as early as
2 days after transcatheter closure. Jia et al. [14] obtained
similar results.
In the present study ET-1 levels further decreased at 6
and 12 months, although the rate of decrease was much
slower after 6 months. The decrease in ET-1 concentration
as early as at 2 days after ASD closure confirms it is a
volume response which depends on a significant reduction
in pulmonary blood flow. In the present study selected
parameters, including hemodynamics and physical capacity,
were compared in two subgroups of patients with the high
and low ET-1 levels. The high ET-1 levels were correlated
with age, right atrial and ventricular enlargement and
elevated pulmonary artery pressure. Patients with ASD
II and high ET-1 had lower peak oxygen consumption and
at the anaerobic threshold and shorter time to anaerobic
threshold corresponding to reduced physical capacity.
Patients with low ET-1 were classified as those in the
first quartile (<2.99 pg/ml) whereas patients with high
Figure 4 ROC curves for selected parameters: [RVarea (cm
2) – green, RAarea (cm
2) – red, PAPs (mmHg) – black and age – blue] and
cut-off values.
Komar et al. Cardiovascular Ultrasound 2014, 12:31 Page 6 of 8
http://www.cardiovascularultrasound.com/content/12/1/31ET-1 as those in the fourth quartile (>6.99 pg/ml). In the
present study we defined the cut-off values of ET-1 above
which we can expect reduced physical capacity and right
atrial and right ventricular enlargement. Measurements of
ET-1 in ASD patients with borderline shunt ratio may
help identify the subjects with elevated pulmonary artery
pressure who may benefit from ASD closure.Figure 5 ROC curves for selected parameters [VO2peak(ml/kg/min) – redThe significant ASD, according to the ESC Guidelines,
is defined as shunt with signs of right ventricular volume
overload despite of Qp:Qs. Also patients who are asymp-
tomatic or mildly symptomatic should be offered defect
closure, because the natural course of untreated atrial
septal defects often leads to a shortened life expectancy
compared with healthy subjects [20,21]. Measurements, FVC (%) – green, VO2AT% – black, TAT – blue] and cut-off values.
Figure 6 Meta-analysis of selected parameters influencing elevated ET-1 levels using the Peto method. Odds ratios (OR) with corresponding
95% confidence intervals (95% CI).
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diagnosis and selection of patients with borderline left-
to-right shunt ratio for suitable intervention. Thus we
could propose transcatheter closure in patients with
ASD with insignificant shunt and high ET-1 levels.
Conversely we could suggest a medical follow-up (versus
closure) in patients with small ASDs with insignificant
shunt and low ET-1 levels. It seems appropriate to con-
sider ET-1 dosage in different populations with congenital
heart disease, where the decision or the timing for inter-
vention is still under debate.
Conclusions
1. The level of plasma Endothelin-1 in patients with
atrial septal defect is elevated in compare to healthy
subject
2. Elevated level of Endothelin-1 in patients with ASD
is associated with right heart enlargement and poor
exercise capacity.
3. After percutaneus closure of secundum ASD using
ASO device the significant reduction of ET level is
observed.
4. Measurements of ET-1 in peripheral blood and
possibly in pulmonary artery may be a supplemental
diagnostic tool and a prognostic indicator and may
be helpful in establishing indications for defect
closure.
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